Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.02 USD | -0.15% | -3.62% | -13.55% |
05-02 | UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating | MT |
05-01 | Alkermes's Q1 Earnings, Revenue Grow But Miss Street View | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.55% | 4.07B | |
+21.76% | 47.9B | |
+46.62% | 41.42B | |
-2.18% | 40.7B | |
-6.20% | 28.92B | |
+10.19% | 25.55B | |
-20.87% | 19.27B | |
-0.32% | 12.15B | |
+31.04% | 12.14B | |
-0.47% | 11.99B |
- Stock Market
- Equities
- ALKS Stock
- News Alkermes plc
- Alkermes Commences Phase 3 Trial of Platinum-Resistant Ovarian Cancer Combination Therapy